2012
DOI: 10.1001/jama.2012.6756
|View full text |Cite
|
Sign up to set email alerts
|

Risks of Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Receiving Warfarin and Treated With Intravenous Tissue Plasminogen Activator

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

5
84
0
5

Year Published

2012
2012
2023
2023

Publication Types

Select...
10

Relationship

3
7

Authors

Journals

citations
Cited by 147 publications
(94 citation statements)
references
References 38 publications
5
84
0
5
Order By: Relevance
“…In the AHA Get With The Guidelines-Stroke (GWTG-Stroke) Registry, adjusted rates of symptomatic intracranial hemorrhage after thrombolysis were not significantly different in 1802 warfarin-treated patients with INRs #1.7, and in 21,635 not-warfarin-treated-patients 4 . Similar results were obtained in 768 warfarin-treated patients with INRs #1.7 and 43,651 not-warfarin-treated patients in the Safe Implementation of Thrombolysis in Stroke (SITS) International Stroke Thrombolysis Register 5 . Results of the A Virtual International Stroke Trials Archive (VISTA) indicated that rtPA has a beneficial effect on functional outcomes in patients with INRs #1.7 6 .…”
supporting
confidence: 69%
“…In the AHA Get With The Guidelines-Stroke (GWTG-Stroke) Registry, adjusted rates of symptomatic intracranial hemorrhage after thrombolysis were not significantly different in 1802 warfarin-treated patients with INRs #1.7, and in 21,635 not-warfarin-treated-patients 4 . Similar results were obtained in 768 warfarin-treated patients with INRs #1.7 and 43,651 not-warfarin-treated patients in the Safe Implementation of Thrombolysis in Stroke (SITS) International Stroke Thrombolysis Register 5 . Results of the A Virtual International Stroke Trials Archive (VISTA) indicated that rtPA has a beneficial effect on functional outcomes in patients with INRs #1.7 6 .…”
supporting
confidence: 69%
“…Układowa tromboliza jest przeciwwskazana u pacjentów otrzymujących OAC o terapeutycznej intensywności [472,473]. U pacjentów leczonych VKA można podawać rtPA, jeżeli INR < 1,7 [474], a u pacjentów leczonych dabigatranem jest to dopuszczalne, jeżeli czas częściowej tromboplastyny po aktywacji (APTT) pozostaje prawidłowy, a od przyjęcia ostatniej dawki leku upłynęło > 48 h (na podstawie opinii ekspertów) [472]. Kwestia, czy można by stosować swoiste antidota odwracające działanie NOAC [475], a potem systemową trombolizę, wymaga zbadania.…”
Section: Leczenie śWieżego Udaru Niedokrwiennegounclassified
“…[6][7][8][9][10][11][12][13][14][15] There are also now randomized trial data from the Third International Stroke Trial (IST-3), which enrolled patients for whom there was equipoise regarding the benefits of thrombolytic therapy and randomized to treatment with IV tPA versus placebo ≤6 hours from onset. 16 This study included 1617 patients aged >80 years and found that although the rate of good outcome in that group was overall lower than younger patients, there was still a significant benefit to treatment with IV tPA.…”
Section: September 2014mentioning
confidence: 99%